UCB Pharma research day—25 October 2007 ‘Glia-neuron interactions and purinergic receptors in neurological disorders’
UCB Pharma asked Geoffrey Burnstock to propose a programme of 8 international leaders in the glia-neuron interaction and purinergic signalling field to participate in a meeting aimed at introducing the topic to about 30 members of the Company to consider the therapeutic potential of purinergic signalling compounds for the treatment of neurological disorders, including: epilepsy, neurodegenerative diseases, movement disorders, neuroprotection, mood disorders and neuropathic pain.
Geoff Burnstock, acting as the Chairman of this 1-day meeting, held at the Château de Limelette, Belgium, introduced the objectives of the meeting. He stressed the sophisticated biology that was involved in drug development and the advantages of collaborations between basic scientists, clinicians and the drug industry in bringing advances in knowledge from basic science to application in clinical medicine for the treatment of disease.
The morning session was devoted to the mechanisms underlying glia-neuron intera
- UCB Pharma research day—25 October 2007 ‘Glia-neuron interactions and purinergic receptors in neurological disorders’
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 4, Issue 1 , pp 79-84
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF, UK
- 2. CNS Pharmacology, Preclinical CNS Research, UCB Pharma, Chemin du Foriest, Building R9, Room 1.1.15, 1420, Braine-l’Alleud, Belgium